Why Dynavax Stock Soared Today
Sanofi is launching an all-cash tender offer for Dynavax's shares. The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price.
Dynavax Technologies Stock Soars on Buyout Buzz
Biotech stock Dynavax Technologies Corp (NASDAQ:DVAX) is soaring today, last seen up 38.7% at $15.43, after reports that Sanofi (SNY) plans to acquire the company in an all-cash deal worth roughly $2.2 billion.
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the shingles vaccine market.
Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.
Dynavax Technologies: A Dip To Accumulate
Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and management is projecting significant sales and market share growth through 2030. Dynavax boasts a robust balance sheet, recently completed a $200M buyback, and is well-regarded by analysts, supporting further accumulation at current valuations.
Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Senior VP & CFO Paul Cox - VP of Investor Relations & Corporate Communications Robert Janssen - Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Ryan Spencer - CEO & Director Conference Call Participants Douglas Royal Buchanan - Citizens JMP Securities, LLC, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Matthew Christopher Phipps - William Blair & Company L.L.C., Research Division Paul Choi - Goldman Sachs Group, Inc., Research Division Philip M.
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago.
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balanced capital allocation program.
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.07 per share a year ago.
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030.
